Back to results
US 2026/0285887 A1Published application
Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
AssigneeSciencons AS
InventorRoy Hartvig Larsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to complexes comprising a prostate-specific membrane antigen (PSMA) targeting compound linked to a radionuclide, such as 212Pb or 227Th, through a TCMC or DOTA chelating moiety. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.
Claims20
A compound comprising a prostate specific membrane antigen (PSMA) binding unit, a linker unit, and a chelating unit, wherein the compound is of the formula,
- p-SCN-Bn-DOTA-PSMA ligand 2
- or a salt thereof.
Dependencies are inferred from the claim text.